Online inquiry

IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6490MR)

This product GTTS-WQ6490MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6490MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3615MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ5234MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ12244MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ11634MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ4431MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ14816MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ4568MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ9025MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC RON-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW